E vEry year in the US, approximately 1.4 million people experience TBIs, resulting in more than 235,000 hospitalizations and 50,000 deaths. 24, 34 Patients who experience severe TBI have a high risk of subsequent injury not only from systemic trauma, but also from secondary ischemic brain injury due to elevated ICP and inappropriately low CPP. Neurosurgeons are often challenged to maintain normal ICP in the setting of TBI. Establishing critical care strategies to combat intracranial hypertension is a cornerstone of saving patients with critically severe TBI. The treatment course for many of these patients involves close neurological observation and ICP monitoring. The neurosurgical community has recently begun to accept aggressive medical strategies in nonsurgical TBI patients to manage elevated ICP. In the largest multicenter evaluation of survival predictors for TBI, Farahvar et al.
Patients who experience severe TBI have a high risk of subsequent injury not only from systemic trauma, but also from secondary ischemic brain injury due to elevated ICP and inappropriately low CPP. Neurosurgeons are often challenged to maintain normal ICP in the setting of TBI. Establishing critical care strategies to combat intracranial hypertension is a cornerstone of saving patients with critically severe TBI. The treatment course for many of these patients involves close neurological observation and ICP monitoring. The neurosurgical community has recently begun to accept aggressive medical strategies in nonsurgical TBI patients to manage elevated ICP. In the largest multicenter evaluation of survival predictors for TBI, Farahvar et al. 11 recently reported a 64% lower risk of death in TBI patients who responded to ICP-lowering therapies. These authors reported that patients who maintained fewer hours of elevated ICP (> 25 mm Hg; p < 0.0001) and those without arterial hypotension on the 1st day of TBI (p = 0.001) have a significantly reduced rate of death 2 weeks after TBI. The study involved more than 1400 patients at 22 centers; 380 of whom were treated for ICP elevation > 25 mm Hg. Therefore, TBI patients with intracranial hypertension require aggressive ICP-lowering therapies that do not cause systemic hypotension early in the course of their hospitalization to provide the best possible chance for recovery.
In a subset of TBI patients, however, elevated ICP will become refractory to standard therapy. Patients in whom Effective treatment of refractory intracranial hypertension after traumatic brain injury with repeated boluses of 14.6% hypertonic saline standard medical and surgical therapies do not adequately lower ICP to allow for physiologically adequate CPP are at an extremely high risk for irreversible damage from brain ischemia, hemorrhage, and herniation syndromes, which could all lead to death. Although previous studies document the treatment of refractory elevation in ICP, the standards used to define refractoriness are quite low. 19, 21, 29, 41, 43, 48 Truly refractory intracranial hypertension is a stage of TBI progression in which treatments may become futile and patients usually succumb to their injuries. The use of hypertonic fluids and mannitol has allowed control of elevated ICP, but only recently has the use of highly concentrated (14.6% or 23.4%) HTS become a mainstay in many neurocritical care units and gained acceptance among neurosurgeons involved in the care of patients with TBI. 2, 14, 15, 19, 27, 28, 30, 36, 41 Since the first reported successes with HTS therapy, its benefits have been touted in the literature. 8, 42 Hypertonic saline infusions at concentrations from 1.6% to 23.4% have shown powerful ICP-lowering effects, 3 and recent data have suggested that HTS has intravascular volume replenishment properties as well as benefits at the cellular level. 1, 17, 25 Although several studies have described the benefits of HTS in controlling elevated ICP and establishing normal CPP, relatively few studies have examined its use for the management of refractory ICP elevation. 23, 41, 48 A literature search revealed that no investigators have monitored ICP, CPP, and other vital signs beyond 6 hours to determine whether the effects of HTS are sustained in the treatment of refractory intracranial hypertension. 19, 33, 41 Moreover, we found studies on nonrepeated boluses of HTS but none utilizing the highest concentrations of HTS (14.6% or 23.4%) for the treatment of severely refractory elevated ICP. [2] [3] [4] [5] [6] 9, 10, [12] [13] [14] [15] [16] [17] 19, 21, 29, [35] [36] [37] [38] 40, 41, 43, 47 Furthermore, no studies have examined the efficacy of 14.6% HTS in the treatment of ICP.
In the current prospective cohort study, we evaluated the efficacy and safety of repeated boluses of 14.6% HTS as a treatment for patients with otherwise refractory intracranial hypertension in the setting of TBI. The effects of repeated boluses of 14.6% HTS were monitored for a period of 12 hours. We hypothesized that there would be a clinically significant reduction in ICP with each bolus of 14.6% HTS and that these effects would be prolonged over 12 hours if repeated boluses were administered.
Methods

Pilot Study
A concentration of 14.6% HTS was selected for this study as a compromise between the well-known 3% HTS and the highest concentration of 23.4% HTS. Provisionally, after proving that 14.6% HTS could be safely used to treat refractory ICP elevation, we would plan for a randomized controlled study of various administration methods of 23.4% HTS for use in elevated global ICP. After obtaining approval from the Pharmacy and Therapeutics Committee to use this concentration at our institution, we developed a protocol for 40-ml boluses of 14.6% HTS (Hospira, Inc.) as an alternative to mannitol in patients with TBI whose ICP remained completely refractory to conventional therapies (see inclusion criteria). We obtained approval from the institutional review board to evaluate the use of 14.6% HTS in these patients with waiver of consent. During a pilot study (20 individual boluses) to assess preliminary safety and efficacy, the boluses contained 50 ml of 14.6% HTS. After efficacy and safety were demonstrated, 40-ml boluses were used because this was the amount within 1 vial of 14.6% HTS. After evaluation of the pilot study data demonstrated no significant difference between using boluses of 40 and 50 ml, all data were included in this cohort study.
Patient Population
Patients in the study were treated in the neurocritical care unit at our large academic teaching hospital and Level 1 trauma center. Eligible patients were older than 17 years of age, had experienced TBI, and subsequently demonstrated severely refractory intracranial hypertension. Intracranial pressure elevation was considered severely refractory if it was sustained at > 30 mm Hg for more than 30 minutes without response to the following ICP-lowering treatments: patient repositioning, relative hypocarbia (arterial blood 33 mm Hg < PaCO 2 < 38 mm Hg) with an alkalotic pH, 3% saline boluses and continuous infusion, sedation (fentanyl, midazolam, or propofol) and paralytic agents (vecuronium or cisatracurium), normothermia (< 37.5°C), external ventricular drainage (if appropriate), and surgical intervention (if appropriate). Patients were excluded if they did not have a continuously recording ICP monitor, experienced renal failure (serum creatinine > 2.0 mg/dl or urine output < 30 ml/hour), had treatment with mannitol within the previous 24 hours, or had a S Na > 175 mEq/L or serum osmolality > 360 mOsm/kg. All patients were treated with standard medical therapy as dictated by the critical care team in this cohort study. At our institution, all patients are treated with best evidence as outlined in the Traumatic Brain Injury Guidelines. 6 Therefore, profound hypotension, hypocapnia, and hypothermia were avoided.
Experimental Protocol
During the period between March 2009 and March 2011, patients with severely refractory ICP despite medical and surgical treatment for TBI were enrolled. The neurointensivist or the nurse with physician supervision administered individual boluses of 14.6% HTS over 15 minutes through central venous access. Each bolus administration of 14.6% HTS (not each patient) was considered an individual exposure for the purposes of this study. Repeated boluses were administered after 60 minutes only if the patient once again met the inclusion criteria for having refractory ICP. At infusion, the ICP, CPP, HR, and SBP were recorded. Serum sodium levels and serum osmolality were recorded per regular intensive care unit protocol, which was usually every 4-6 hours. Subsequent recordings of ICP, CPP, HR, and SBP occurred as follows: every 5 minutes for 30 minutes, every 15 minutes for 1 hour, and every hour for 12 hours. Evaluation of ICP and CPP changes restarted at Time 0 with each new infusion of 14.6% HTS. If ICP elevations continued past 12 hours, then 14.6% HTS boluses were administered again.
The primary outcome of this study was the efficacy of repeated 14.6% HTS boluses in lowering ICP in the setting of severely refractory intracranial hypertension. To determine this outcome, the preadministration ICP (Time 0) was compared with the 12-hour time point after bolus initiation. Secondary outcomes included evaluation of changes in CPP, HR, and SBP from Time 0 to each subsequent time point starting 5 minutes after initiation of the bolus. Treatment effect was measured as a statistically significant reduction in ICP at each recorded time point compared with the baseline ICP at the time of initiation of the bolus. Safety assessments included monitoring of hemodynamic status (HR and SBP), electrolyte status (S Na , potassium and chloride levels, and osmolality), renal function (blood urea nitrogen and creatinine levels), pCO 2 , and pH levels (from blood gas readings).
Statistical Analysis
Prior to initiation of the prospective cohort study, a power analysis was performed. We predicted a 20% decrease in ICP from baseline (Time 0) at 12 hours. 19, 23, 41, 48 For a power of 0.8 (beta error of 20%), a total of 9 individual doses would have been required. Inclusion of at least 56 doses raised the estimated power to 0.99. Normalization tests that screen the mean values of outcome variables across the time points were used prior to statistical analysis. Analysis of variance and post hoc Scheffé tests were performed on the primary outcome of ICP change from pre-HTS bolus levels. Values at all time points (starting 5 minutes after initiation of bolus) were compared with baseline values and with values at the 12-hour time point. Statistical analyses of secondary and safety outcomes, including CPP, HR, SBP, S Na , and serum osmolality, are also reported. Data reported as the means ± standard deviations were drawn from normal distributions. A Scheffé post hoc analysis was performed with the Bonferroni correction, and statistical significance was set at p < 0.05.
Results
During the 2-year accrual, 11 patients and 56 boluses were included in this study (Table 1) . Two patients had craniectomies, 10 had external ventricular drains, and 1 had no surgical intervention besides placement of an ICP monitor. All surgical procedures were performed according to the attending neurosurgeon's clinical decision making. The 14.6% HTS boluses were administered according to the inclusion/exclusion criteria regardless of surgical procedures. Only 2 patients (Cases 10 and 11) had surgical interventions after initiation of the 14.6% HTS boluses. One of these patients survived, requiring decompression from a traumatic subdural hematoma, followed by replacement of a bone flap and ventriculoperitoneal shunt placement. The other patient did not survive because the family elected to withdraw care. Although 14.6% HTS boluses were delivered over 15 minutes, mean ICP measurements decreased from 40 ± 12 mm Hg at baseline to 33 ± 10 mm Hg within 5 minutes of bolus initiation (p < 0.05; Fig. 1 ). By 10 minutes, there was a reduction in mean ICP to 28 ± 9 mm Hg (p < 0.05) even though the bolus was not yet completed. Reduction of ICP compared with baseline continued through the first 60 minutes of recording (p < 0.05).
For patients in whom full 12-hour measurements were available, all had received multiple boluses of 14.6% HTS to maintain adequate ICP reduction (Fig. 2) . Within the 12-hour timeframe, repeated administration of 14.6% HTS boluses was allowed if patients once again met the inclusion criteria. For these patients, a statistically significant reduction in ICP from baseline was maintained if repeated boluses were administered. The mean ICP was lowered by 41%, from 40 ± 12 mm Hg at baseline to 23 ± 9 mm Hg at 12 hours (p < 0.05).
There was no restriction on the number of additional boluses given as long as patients continued to meet the inclusion criteria. In the majority of boluses, prolonged ICP reduction effects were generated from repeated administration of additional boluses, with the overall duration of treatments being greater than 12 hours for multiple patients. By 4 hours after the first dose of 14.6% HTS, 10 doses of 14.6% HTS were repeated; by 8 hours after the first dose, 32 doses were repeated; and by 12 hours after the first dose, 42 doses were repeated. Thirteen single boluses of 14.6% HTS led to sustained ICP < 30 mm Hg for more than 12 hours. Of the total repeated boluses, 24 resulted in an ICP < 30 mm Hg for 12 or more hours and 3 resulted in ICP < 30 mm Hg for more than 72 hours. A mean of 7 ± 5.5 boluses were given per patient.
Cerebral perfusion pressure measurements showed similar trends and significance, with elevation in the mean CPP seen immediately from 60 ± 12 mm Hg at baseline to 63 ± 16 mm Hg at 5 minutes (p < 0.05; Fig. 1 lower) . Within 20 minutes of bolus initiation, mean CPP had risen to 77 ± 13 mm Hg (p < 0.05). After the 5-minute time point, mean CPP did not drop below 70 mm Hg throughout the 12-hour recording period. After multiple boluses of 14.6% HTS by 12 hours, mean CPP was 70 ± 10 mm Hg (18% increase compared with baseline). Although various vasopressor agents were used to maintain appropriate CPP goals under our standard clinical CPP management protocol (goal CPP: 50-70 mm Hg), once 14.6% HTS boluses were administered and ICP was reduced, vasoactive agents used for the maintenance of mean arterial pressure and CPP were reduced (data not shown).
The mean HR and SBP did not change significantly during HTS infusions or for the 12-hour recording period thereafter (Fig. 3) . Measurements of S Na and osmolality showed an appropriate increase of 2-3 mEq/L after initiation of each 14.6% HTS bolus; however, even after multiple boluses of 14.6% HTS, the mean S Na at all time points up to 12 hours did not change significantly (p > 0.05). The mean S Na at initiation of 14.6% HTS boluses was 155 ± 7.1 mEq/L, and mean S Na at 12 hours after initiation of dosing was 154 ± 7.1 mEq/L (Fig. 4) . The maximum S Na at the initiation of treatment with 14.6% HTS was 173 mEq/L in a single patient, but it counterintuitively decreased to 172 mEq/L at 10 hours. Serum osmolality showed similar trends, without a clinically or statistically significant rise in mean osmolality throughout the 12-hour recording period (p > 0.05): the mean serum osmolality at Time 0 (327 ± 11.5 mOsm/kg) and 12 hours after repeated boluses (327 ± 7.5 mOsm/kg) were not significantly different. The maximum serum osmolality initially after bolus in any patient was 358 mOsm/kg at 3 hours after administration of 14.6% HTS. Serum values of blood urea nitrogen and creatinine were recorded as a marker of renal function. These values were not only used for inclusion criteria as stated above, but were also monitored throughout the pre-and postbolus periods for each bolus of 14.6% HTS administered. Serum values of potassium, chloride, and bicarbonate were also assessed for clinically significant changes before and after bolus administration (Table 2) . No statistically or clinically significant differences were noted in the serum blood urea nitrogen, creatinine, potassium, chloride, or bicarbonate levels throughout this study. No patients were prevented from receiving 14.6% HTS boluses because of S Na or serum osmolality levels.
Outcomes were measured using the GOS at 6 and 12 months postdischarge ( Table 1 ). The GOS score for each of the 4 patients who survived was between 3 and 5 at 6 months and again at 12 months. Two of the 4 patients improved their GOS scores between 6 and 12 months (from GOS Score 3 to 4 and from 4 to 5), and scores remained unchanged in 2 patients (GOS Score 3 to 3 and 5 to 5). The GOS score did not worsen in any of these patients after discharge from the hospital.
Discussion
The major finding of this study is that repeated boluses of highly concentrated (14.6%) HTS can treat severely refractory intracranial hypertension, even in the setting of malignant ICPs of 40-50 mm Hg and high pre-dose S Na and osmolarities. Although the use of single-dose, highly concentrated osmotic agents has been described for otherwise refractory intracranial hypertension, 41, 48 the administration of repeated boluses of highly concentrated HTS in a population of patients with completely refractory ICP elevation has yet to be documented in the literature. Our study suggests that this method of controlling severely refractory ICP is not only safe, but also highly effective.
In the late 1980s, interest in HTS was generated based on a few favorable case reports. 48 Since then, multiple human and animal studies have supported the beneficial effects of HTS therapy. In an animal study, da Silva et al. 10 used a rabbit model to induce a potentially lethal increase in ICP by inflating an intracranial balloon, then compared equimolar doses of 10% HTS and 20% mannitol as acute treatment. Animals in the study survived, on average, 53 minutes with an ICP of 50 mm Hg without treatment. Animals treated with HTS showed statistically significant lowering of ICP and elevation of CPP as well as a survival benefit. Qureshi and colleagues 31, 32 have published several studies on the use of a single bolus of 23.4% HTS to reverse unilateral hematoma-induced transtentorial herniation in a dog model. They also demonstrated impressive increases in regional cerebral blood flow within both the ipsilateral and contralateral cortex as well as the thalamus, compared with significant decreases in regional cerebral blood flow before treatment. 32 One important aspect of the study by Qureshi et al. is that a bolus of highly concentrated HTS was able to reverse a potentially life-threatening condition, namely, transtentorial herniation. These animal models share similarities with our population of patients with severely refractory intracranial hypertension, in which clinical signs indicated that all patients enrolled would have died of uncontrollable ICP.
Hypertonic saline boluses of 23.4% have also been shown to reverse transtentorial herniation in a retrospective human study by Koenig et al. 23 Human studies on HTS treatment vary with respect to the concentration of saline used (1.6%-23.4%) and the volume of infusion (30-250 ml), but in 2009, Strandvik 40 evaluated 26 clinical trials that utilized HTS for the treatment of elevated ICP in brain injury and found the most common treatment concentration studied was 7.5% saline in 2-ml/kg bolus doses. Of these 26 studies, 15 specifically examined HTS in patients with TBI. Five were case-control studies 14, 17, 21, 28, 36 that showed that HTS boluses could significantly reduce ICP in patients with elevated ICP refractory to mannitol therapy. Conversely, Shackford et al. 37 reported that HTS is not more effective than lactated Ringer solution in lowering ICP in a group of 34 adults with TBI; however, it is important to note that the HTS group had more severe head injuries as a potential confounding vari- able, and thus making these conclusions weak. Despite this and other clinical and experimental studies that have reported mixed data regarding the efficacy of HTS in the treatment of elevated ICP, other scientifically rigorous studies have shown beneficial effects with few side effects or detrimental consequences. Fisher et al. 12 and Simma et al. 38 showed that HTS is more effective than normal saline or lactated Ringer solution in lowering ICP in children. Harutjunyan and colleagues 15 also showed an increase in CPP, which was used as a surrogate marker for brain perfusion. Francony et al. 13 revealed the efficacy of HTS in significantly lowering ICP and increasing CPP but did not demonstrate superiority to equimolar doses of mannitol. In the most recent and largest meta-analysis of published data evaluating the efficacy of HTS in treating elevated ICP, Mortazavi and colleagues 27 reviewed 36 articles on the subject. Although inconsistent protocols and limited data made conclusive recommendations difficult, these authors importantly concluded that the literature supports HTS, either bolus or infusion, as superior to mannitol in lowering elevated ICP.
Mannitol administered with the hope of reducing ICP is considered the mainstay of potentially life-saving measures for clinically refractory intracranial hypertension by many, if not all, neurointensivists and neurosurgeons. Based on past empirical experience and numerous published studies, the beneficial effects of mannitol have often been short lived and potentially caused refractory elevation in ICP worse than originally encountered. 2,7,10,13-15, 17,18,20,22,26,27,29,31,39,43,45,46,49 Potentially lethal rebound intracranial hypertension as well as systemic hypotension has been reported with mannitol administration. Concomitant dangerous decreases in CPP, which can lead to brain tissue ischemia, stroke, and even death, argue against the use of mannitol alone in the setting of elevated ICP. Graph showing S Na and serum osmolality levels over the 12-hour experimental period. Normal laboratory range is shown as a shaded region (plotted means ± standard deviation). Upper: Starting levels of S Na were always above normal range, but no significant increase from Time 0 was noted with repeated boluses of 14.6% HTS through the 12-hour experimental period. Lower: Similar trends were noted in serum osmolality, where starting values were significantly above normal laboratory range, but no significant increase was noted with repeated boluses.
Ours is the only reported study that combines the use of repeated boluses of highly concentrated HTS for the treatment of severely refractory intracranial hypertension in patients who have TBI with monitoring of the ICPlowering effects for a period of 12 hours. Twelve hours of highly meticulous vital sign, ICP, and CPP recordings is the longest that we could find in the literature. Nevertheless, the study has some limitations. It is a nonrandomized nonblinded study, and two different volumes of 14.6% boluses were included in the final analysis, although no significant differences were realized between boluses in the pilot portion of the study. Despite the large number of individual boluses to analyze, the number of patients in the study might be considered small (11 patients and 56 boluses); however, given the statistical power that was achieved in this very specific patient population-namely, TBI patients in whom all traditional methods to lower ICP had been exhausted-this number could be considered adequate. In the future, more detailed outcome studies on this patient population along with randomization of treatment methods, including different methods of HTS bolus administration, would be helpful in determining the superiority of various treatments.
Conclusions
We have demonstrated for the first time that patients with severely refractory intracranial hypertension from TBI can be treated effectively and safely with repeated boluses of 14.6% HTS and that ICP-lowering effects after repeated boluses are maintained for extended periods of time (12-72 hours). Furthermore, ICP-lowering effects can be achieved with HTS even in the face of substantially elevated S Na and osmolarity levels. A concentration of 23.4% HTS is the most commonly used highly concentrated HTS at this time, 27, 31, 32, 44 but studies of 23.4% HTS have been limited by the use of a single bolus and by the duration of the monitoring of therapeutic effects after the bolus is administered. On the basis of the efficacy of repeated 14.6% boluses, future studies will examine the efficacy of multiple boluses of HTS, with respect to concentration, timing, and rate of administration, for the treatment of highly refractory ICP in patients with severe TBI and other critical neurological illness. Although only a small percentage of patients with severe TBI will ever have severely refractory ICP, we have demonstrated the utility of an additional hyperosmolar therapeutic agent in the armamentarium of the neurosurgeon that can be used in repeated boluses, instead of a one-time dose, for longerlasting ICP control. These findings offer the possibility that with the use of highly concentrated osmotic agents in a repeated manner, patients may survive previously lethal intracranial hypertension.
Disclosure
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
Author contributions to the study and manuscript preparation include the following. Conception and design: all authors. Acqui sition of data: all authors. Analysis and interpretation of data: Hoesch, Eskandari, Filtz. Drafting the article: Hoesch, Eskandari, Filtz.
Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the man uscript on behalf of all authors: Hoesch. Statistical analysis: Es kandari, Filtz.
